|Articles|January 28, 2022
Next-level Diagnosis and Compliance
Panelists provide pearls on how to make a smarter diagnosis, tailor treatment plans to patients’ lifestyles and preferences, and motivate pediatric patients to adhere to their treatment plan.
Advertisement
Advertisement
Related to this article
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Children with FASD given choline before age 6 had 9.1% higher nonverbal IQ and 11.3% better working memory vs placebo 5 years after treatment.
A deep learning model reading 1 nondilated fundus photo predicted 1-year progression to high myopia in children with AUCs of 0.91-0.96.
Todd Wolynn, MD, MMM, FAAP, explains how pediatricians can address misinformation through empathetic communication and community engagement.
SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA sets new PDUFA date for Anaphylm for type I allergic reactions
2
Youth-onset type 2 diabetes may progress faster, signs easy to miss
3
When one young athlete’s cardiac arrest revealed a family at risk
4
SUID drives widening Black-White infant mortality gap since 2020
5